Dark

KZIA
Kazia Therapeutics Limited
stock NASDAQ ADR

Market Open

Oct 20, 2025 1:13:33 PM EDT

7.04USD+0.571%(+0.04)18,111

0.00Bid 0.00Ask 0.00Spread

Pre-market

Oct 17, 2025 8:51:30 AM EDT

7.08USD+1.113%(+0.08)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 25, 2022

08:02AM EST KAZIA THERAPEUTICS TO PARTICIPATE IN EDISON GROUP'S GLOBAL HEALTHCARE 'OPEN PR Newswire

Jan 7, 2022

08:01AM EST KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT BIOCONNECT CONFERENCE PR Newswire

Dec 13, 2021

11:29AM EST Kazia Therapeutics Appoints Karen Krumeich As CFO RTTNews

11:01AM EST KAZIA THERAPEUTICS APPOINTS KAREN KRUMEICH AS CHIEF FINANCIAL OFFICER PR Newswire

06:08AM EST A Peek Into The Markets: US Stock Futures Gain After S&P 500 Hits Record High Benzinga

04:49AM EST Kazia Therapeutics Named Karen Krumeich as Chief Financial Officer Benzinga

Dec 4, 2021

08:00AM EST Kazia Announces Positive Final Data From Phase II Clinical Study Of Paxalisib PR Newswire

Dec 3, 2021

05:16AM EST Kazia Announced Final Data From Phase II Clinical Study of Paxalisib in Newly Diagnosed Glioblastoma Confirm Previously Reported Safety and Efficacy Profile Benzinga

Nov 29, 2021

08:06AM EST Kazia Therapeutics Announces The GBM AGILE Study In Glioblastoma Has Opened At Sunnybrook Health Sciences Centre In Toronto, Ontario Benzinga

08:00AM EST GBM AGILE Opens to Paxalisib in Canada PR Newswire

Nov 15, 2021

11:05AM EST Kazia Therapeutics Appoints John Friend As Chief Medical Officer RTTNews

11:00AM EST Kazia Therapeutics Appoints John Friend, MD, as Chief Medical Officer PR Newswire

10:47AM EST A Peek Into The Markets: US Stock Futures Higher Ahead Of Tyson Foods Earnings Benzinga

10:41AM EST Kazia Therapeutics Named John Friend, MD, as Chief Medical Officer Benzinga

Nov 11, 2021

08:05AM EST Kazia Therapeutics Limited Initiates PNOC022 Multi-Drug Phase II Study In DIPG, Has Enrolled First Patient Benzinga

08:00AM EST PNOC Study in Childhood Brain Cancer Enrols First Patient PR Newswire

Nov 10, 2021

06:01PM EST Kazia Therapeutics Enrolls First Patient In PNOC Study In Childhood Brain Cancer Benzinga

08:24AM EST Kazia Therapeutics Sponsored Study Titled 'Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours' Posted To ClinicalTrials.gov; Study Is Recruiting Benzinga

Nov 4, 2021

08:02AM EDT Kazia Enrols First Patient to EVT801 Phase I Clinical Trial PR Newswire

05:46AM EDT Kazia Therapeutics Announced it Enrolled First Patient to EVT801 Phase I Clinical Trial Benzinga

Nov 3, 2021

12:58PM EDT Kazia Therapeutics Option Alert: Jun 17 $2.5 Calls at the Ask: 43 @ $9.63 vs 0 OI; Earnings 11/16 Before Open [est] Ref=$11.96 Benzinga

Oct 14, 2021

11:18AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021 Benzinga

08:28AM EDT Maxim Group Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $18 Benzinga

Oct 6, 2021

10:02AM EDT Kazia Therapeutics to Present at LD Micro Main Event PR Newswire

10:01AM EDT Kazia Therapeutics To Present At LD Micro Main Event From Oct. 12-14 Benzinga

Sep 10, 2021

12:30PM EDT Kazia Therapeutics to Present at HC Wainwright 23rd Annual Global Investment PR Newswire

Sep 2, 2021

05:35AM EDT Kazia Therapeutics Announced EVT801 Phase I Study Receives Full Regulatory Approval in France Benzinga

Jul 21, 2021

10:00AM EDT Kazia Calls for Increased Focus on Brain Cancer Research this GBM Awareness Day PR Newswire

Jun 30, 2021

10:03AM EDT Kazia Updates On Paxalisib And EVT801 Clinical Programs RTTNews

10:02AM EDT Kazia Provides Progress Update On Paxalisib And EVT801 Clinical Programs Benzinga

Jun 24, 2021

06:05AM EDT Kazia Therapeutics Announced Manufacturing Patents Granted for Paxalisib in Key Territories; Extend Effective Patent Protection to 2036 Benzinga

Jun 15, 2021

10:04AM EDT Kazia Collaborates With Cornell University For Phase II Study Using Paxalisib-Ketogenic Diet For Glioblastoma RTTNews

10:01AM EDT Clinical Study Using Paxalisib in Combination With Ketogenic Diet for Glioblastoma PR Newswire

05:29AM EDT Kazia Therapeutics on Monday, Announced Clinical Collaboration With Cornell University for Phase II Clinical Study Using Paxalisib in Combination With Ketogenic Diet for Glioblastoma Benzinga

Jun 7, 2021

08:29AM EDT Kazia Therapeutics Enrols First Patient In Phase II Study Of Paxalisib In Primary CNS Lymphoma RTTNews

08:02AM EDT Kazia Therapeutics Reports Initiation Of Phase 2 Study For Co.'s Central Nervous System Lymphoma Candidate, First Patient Enrolled Benzinga

08:02AM EDT Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute PR Newswire

Jun 3, 2021

07:01AM EDT Kazia Therapeutics to Present at LD Micro Invitational XI PR Newswire

Apr 19, 2021

05:40AM EDT Evotec Grants Kazia Worldwide License To Develop, Manufacture, And Commercialise EVT801 RTTNews

05:37AM EDT Kazia Licenses Global Rights to EVT801, a Novel, First-in-Class, Clinic-Ready, PR Newswire

05:17AM EDT Kazia Therapeutics Announced Worldwide Exclusive Licensing Deal & Master Services Deal With Evotec SE Benzinga

03:07AM EDT Evotec SE (EVTCY.PK, EVOTF.PK) said Monday that it reached a licensing and master service agreement with Kazia Therapeutics Limited (KZIA). RTTNews

Apr 15, 2021

07:01PM EDT Kazia Therapeutics Shares Were Halted on the ASX; Pending Conclusion of Negotiations Regarding Potential in-licensing Transaction Benzinga

Mar 30, 2021

07:44AM EDT Kazia Therapeutics Announces Co. Has Signed An Agreement With Simcere Pharmaceuticals For The Greater China Rights To Paxalisib For $7M Upfront And Up To $281M In Potential Milestone Payments And Royalties In The Mid-Teens Benzinga

Mar 29, 2021

06:49AM EDT Kazia Therapeutics Stock Is Trading Higher On Paxalisib Licensing Agreement In Greater China Benzinga

06:25AM EDT Kazia Therapeutics Shares to Resume Trading at 6:30am ET Benzinga

05:27AM EDT Kazia Announced it has Licensed the Rights to Paxalisib in Greater China to Simcere Pharmaceutical Group; Kazia to Receive an Upfront Payment of US $11M Plus Milestone Payments Up to $281M Benzinga

05:21AM EDT Kazia Therapeutics Enters Licensing Agreement With Simcere Pharmaceutical To Develop Paxalisib RTTNews

05:17AM EDT Kazia Licenses Rights to Paxalisib in Greater China to Simcere, a Leading PR Newswire

Mar 1, 2021

10:02AM EST Kazia Reports Licensing Of Cantrixil, First-In-Class Ovarian Cancer Drug Candidate To Oasmia Pharma; Oasmia To Make Upfront Payment Of $4M To Co., With Contingent Milestone Payments Of Up To $42M Benzinga

10:01AM EST Kazia Licenses Cantrixil, a Clinical-stage, First-in-class Ovarian Cancer Drug PR Newswire

08:39AM EST Kazia Therapeutics Licenses Cantrixil To Oasmia Pharmaceutical For Ovarian Cancer Benzinga

05:18AM EST Kazia Announced it Licensed Cantrixil to Oasmia Pharmacetical AB; Kazia to Receive $4M Upfront Plus Milestone Payments Up to $42M and Royalties Benzinga

Feb 25, 2021

05:35AM EST Kazia Therapeutics Priced 391,500 Share Offering @AU$ 0.6351/Share Benzinga

Feb 24, 2021

05:15AM EST Kazia Therapeutics Reported H1 Loss of $6,363,560 vs $5,881,185 YoY Benzinga

Jan 29, 2021

05:14AM EST Kazia Therapeutics Reported Cash Position of A$19.366M as of December 31, 2020 Benzinga

Jan 7, 2021

05:09AM EST Kaizia Reported GBM AGILE Pivotal Study (NCT03970447) has Commenced Recruitment to the Paxalisib Arm Benzinga

Jan 6, 2021

01:07PM EST Kazia Therapeutics Shares Move Higher On Volume Following Press Release From Global Coalition For Adaptive Research Highlighting News GCAR, Kazia, Kintara Began Kazia's Paxalisib, Kintara's VAL-083 In Glioblastoma Adaptive Global Innovative Learning Envir Benzinga

Jan 5, 2021

10:11AM EST Benzinga's Top Upgrades, Downgrades For January 5, 2021 Benzinga

06:09AM EST HC Wainwright & Co. Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $17 Benzinga

Jan 4, 2021

06:51PM EST Kazia Therapeutics Releases Presentation for H.C. Wainwright BIOCONNECT to be Held on January 5, 2021 Benzinga

Dec 13, 2020

06:23PM EST Kazia Therapeutics Releases Presentation to be Made by CEO Dr James Garner at 13th Annual LD Micro Main Event on Monday December 14 Benzinga

Dec 10, 2020

10:02AM EST Kazia To Collaborate With Pacific Pediatric Neuro-Oncology Consortium For Paxalisib Combination Study In DIPG RTTNews

10:02AM EST Kazia Reports Collaboration With Pacific Pediatric Neuro-Oncology Constortium For New Paxalisib Combo Study In Diffuse Intrinsic Pontine Glioma Benzinga

10:01AM EST Kazia to Collaborate with Pacific Pediatric Neuro-Oncology Consortium (PNOC) PR Newswire

Dec 9, 2020

10:38AM EST Cantrixil Phase I Study Confirms Prior Positive Efficacy & Safety Signals In Persistent/recurrent Ovarian Cancer RTTNews

10:30AM EST Top-line Final Data from Cantrixil Phase I Study Confirms Prior Positive PR Newswire

10:30AM EST Kazia Therapeutics Reports Top-Line Final Data From Cantrixil Phase 1 Study Benzinga

Nov 20, 2020

08:06AM EST The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger Benzinga

Nov 19, 2020

08:17AM EST The Daily Biotech Pulse: Aquestive's Positive FDA Meeting, Prevail Awarded Patent, Neuro-Oncology Conference Gets Underway Benzinga

Nov 18, 2020

03:26PM EST Why Kazia Therapeutics Stock Is Trading Higher Today Benzinga

01:19PM EST Yahoo Finance Trending Stocks For Wednesday, Nov. 18, 2020: NKLA, BA, TGT, LOW, PFE, NIO, NAKD, SPCE, RIOT, QCOM, CIIC, KOD, BYND, RIDE, GM, DNK, SCKT, F, JMIA, ROOT, TJX, PCG, IDEX, BABA, MFGP, RIG, XXII, KZIA Benzinga

01:17PM EST Stocktwits Trending Stocks For Wednesday, Nov. 18, 2020: TSLA, BA, FCEL, NKLA, RIDE, CIIC, BB, THCB, CRSR, KZIA Benzinga

07:30AM EST The Daily Biotech Pulse: Kazia Jumps On Data Readout, Clinical Hold On Cellectis' Blood Cancer Study Lifted Benzinga

Nov 17, 2020

05:48PM EST Kazia Presents Further Paxalisib Data At Sno, Confirming Earlier Positive PR Newswire

04:59PM EST Kazia Therapeutics Announces At The SNO Further Paxalisib Data Confirming The Earlier Announced Positive Safety And Efficacy Signals In Glioblastoma Benzinga

08:32AM EST The Daily Biotech Pulse: Setback For Alkermes, Boston Scientific's Recall, ALX-Zymeworks Oncology Collaboration Benzinga

Nov 16, 2020

10:02AM EST 68 Stocks Trading Near 52-Week Highs Just After Open On Monday, Nov. 16, 2020: Benzinga

Oct 16, 2020

10:32AM EDT Kazia Executes Deal To Commence GBM Agile Pivotal Study RTTNews

10:31AM EDT Kazia Executes Agreement To Commence GBM Agile Pivotal Study Of Paxalisib As A Treatment For Glioblastoma, Recruitment Expected To Begin In Q1 2021 Benzinga

10:30AM EDT Kazia Executes Agreement To Commence GBM Agile Pivotal Study PR Newswire

Oct 7, 2020

06:42PM EDT Kazia Therapeutics Announces Retail Entitlement Offer; 1 for 3 Accelerated Pro-rata Non-renounceable Entitlement Offer of Fully Paid Ordinary Shares In Kza at an Offer Price of $0.80 /New Share Benzinga

Oct 2, 2020

07:11AM EDT Kazia Therapeutics Shares Were Scheduled To Reopen At 7 a.m. EDT, Don't Yet See Price Action Benzinga

06:46AM EDT Kazia Therapeutics Limited ADS Shares To Resume Trade At 7:00 a.m. EDT Benzinga

Sep 29, 2020

08:06PM EDT Kazia Therapeutics Ltd - Requests Trading Halt Pending an Announcement About Non-renounceable Entitlement Offer Benzinga

Sep 22, 2020

10:07AM EDT Kazia Reaches Clinical Collaboration With Dana-farber Cancer Institute For Primary CNS Lymphoma RTTNews

10:01AM EDT Kazia Enters Clinical Collaboration With Dana-farber Cancer Institute For PR Newswire

05:16AM EDT Kazia Announced Clinical Collaboration With Dana-farber Cancer Institute For Primary CNS Lymphoma Benzinga

Aug 24, 2020

06:12AM EDT A Peek Into The Markets: US Stock Futures Surge As FDA Authorizes Convalescent Plasma For Coronavirus Treatment Benzinga

Aug 23, 2020

09:15PM EDT FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPG Benzinga

09:04PM EDT US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, PR Newswire

08:55PM EDT FDA Awards Orphan Drug Designation To Paxalisib For Malignant Glioma, Including DIPG RTTNews

08:30PM EDT US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, PR Newswire

Aug 20, 2020

10:32AM EDT Kazia : FDA Awards Fast Track Designation To Paxalisib For Glioblastoma RTTNews

10:30AM EDT US FDA Awards Fast Track Designation (FTD) to Paxalisib for Glioblastoma PR Newswire

05:35AM EDT Kazia Releases US PR Regarding FDA Fast Track Designation for Paxalisib for Glioblastoma, ASX PR Was Released Last Night Benzinga

Aug 19, 2020

07:14PM EDT Kazia Therapeutics Shares Rise 45% After-Hours After Co Says FDA Granted Fast Track Designation for Paxalisib Benzinga

07:07PM EDT Kazia Therapeutics Says FDA Granted Fast Track Designation for Paxalisib Benzinga

06:43PM EDT Kazia Therapeutics Says FDA Granted Fast Track Designation to Kazia's Paxalisib Benzinga

Aug 7, 2020

10:32AM EDT Kazia Therapeutics : FDA Grants Rare Pediatric Disease Designation To Paxalisib For DIPG RTTNews

10:30AM EDT US FDA Grants Rare Pediatric Disease Designation (RPDD) to Paxalisib for DIPG PR Newswire

10:12AM EDT Mid-Morning Market Update: Markets Open Lower; US Unemployment Rate Drops To 10.2% Benzinga

Aug 6, 2020

07:30PM EDT Kazia Therapeutics Says FDA Grants Rare Pediatric Disease Designation to Paxalisib for Diffuse Intrinsic Pontine Glioma Benzinga

Jul 15, 2020

02:20PM EDT Kazia Shares Halted On Volatility, Up 33% Benzinga

02:20PM EDT Kazia Shares Resume Trading; Move Up, Shares Up 33% Benzinga

02:19PM EDT Kazia Therapeutics Shares Halted On Volatility At 2:14 p.m. EDT, Up 21%, After Traders Circulate Promotional Twitter Commentary Benzinga